Starboard Chief Criticizes Pfizer's R&D Investments

An activist hedge fund has raised concerns about Pfizer's current challenges, attributing them to low expected returns on research and development (R&D) investments. This includes investments made both internally and through mergers and acquisitions. The CEO of the fund, which holds a significant stake in Pfizer, emphasized the importance of the pharmaceutical company's board prioritizing the monitoring of R&D investment returns. He also stressed the need for accountability within the company's management to address these issues effectively.